Chloe Pierret

Chloe Pierret

Auto-generated profile, based on publicly available information

Chloe Pierret

Rennes University, École des Hautes Etudes en Sante Publique, Rennes, France

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 November 2024 in Neurology
Verified
Journal Article
Open access
CPChloe Pierret
Chloe Pierret
AMAurélien Mulliez
Aurélien Mulliez
CBChristine Le Bihan-Benjamin
Christine Le Bihan-Benjamin
XMXavier Moisset
Xavier Moisset
PBPhilippe-Jean Bousquet
Philippe-Jean Bousquet
ELEmmanuelle Leray
Emmanuelle Leray
Previous literature has been diverging on cancer risk in people with multiple sclerosis (PwMS). Therefore, this study compared the risk of cancer in PwMS and a matched sample from the French general population. This 10-year nationwide retrospective matched cohort study (2012–2021) used data from the national French administrative health care database (99% coverage of the French population) to determine the time to the first incident cancer. PwMS were identified using their long-term disease (LTD) status, hospitalizations, and multiple sclerosis (MS)–specific drug reimbursements. The control population was matched 4:1 on age, sex, residence, insurance scheme, and cohort entry date. Participants were included if they had no history of cancer in the 3 years before inclusion. Patients with cancer were identified through LTD status, hospitalizations, chemotherapy, radiotherapy, or prostate cancer–specific drug reimbursements. Overall and cancer location–specific hazard ratios (HRs) for the first incident cancer were obtained from Fine and Gray models, and age- and sex-stratified estimates were reported. Participation in cancer screening through the 3 national programs (breast, colorectal, and cervical) were compared between groups. Cancer incidence was 799 per 100,000 person-years (PYs) (n = 8,368) among the 140,649 PwMS and 736 per 100,000 PYs (n = 31,796) among the 562,596 matched controls (70.8% of women; follow-up: 7.6 ± 3.2 years). A small overall risk increase was observed for PwMS (HR 1.06, 95% CI 1.03–1.08), mostly in women (HR 1.08, 95% CI 1.05–1.11). Risk varied by cancer types and was lower for prostate (HR 0.80, 95% CI 0.73–0.88), breast (HR 0.91, 95% CI 0.86–0.95), and colorectal (HR 0.90, 95% CI 0.84–0.97) cancer and higher for bladder (HR 1.71, 95% CI 1.54–1.89), brain (HR 1.68, 95% CI 1.42–1.98), and cervical (HR 1.24, 95% CI 1.12–1.38) cancer in PwMS. Cancer risk was higher in PwMS younger than 55 years (HR 1.20, 95% CI 1.15–1.24) but decreased in PwMS aged 65 years and older (HR 0.89, 95% CI 0.85–0.94). This trend was found in all cancer locations. There were fewer PwMS getting screened than controls (all programs), with a particularly pronounced difference among those aged 65 years and older. Cancer risk was slightly increased in PwMS, particularly for urogenital cancers, possibly due to surveillance bias. Risk fluctuated depending on age, perhaps due to varying generational screening practices (i.e., diagnosis neglect in the older PwMS) and risk factors.

28 February 2024 in Revue Neurologique
Verified
Journal Article
Closed access
CPC. Pierret
C. Pierret
MMM. Mainguy
M. Mainguy
ELE. Leray
E. Leray

10 January 2025 in Multiple Sclerosis Journal
Verified
Journal Article
Closed access
CLChristine Lebrun-Frenay
Christine Lebrun-Frenay
SKSandrine Kerbrat
Sandrine Kerbrat
DODarin T Okuda
Darin T Okuda
CLCassandre Landes-Chateau
Cassandre Landes-Chateau
OKOrhun H Kantarci
Orhun H Kantarci
ELEmmanuelle Leray
Emmanuelle Leray
Background: Previous studies have shown that people with multiple sclerosis (MS) had frequent healthcare visits up to 10 years before being diagnosed but with no information from magnetic resonance imaging (MRI) scans of the connection with the radiologically isolated syndrome (RIS). Objective: To analyze healthcare use 3 years before the RIS diagnosis. Methods: We examined healthcare usage before the first scan in RIS cases from 2010 to 2019. RIS subjects were identified from the French National MS observatory and compared to the general population (matched 10:1) and MS patients (matched 4:1). Results: Among 482 RIS individuals, 223 (46.3%) were not linked to the healthcare resources database. The remaining RIS individuals (53.7%) had higher healthcare usage before their RIS diagnosis for issues related to neurology visits, headaches (odds ratio (OR): 3.34, confidence interval (CI): [2.00–5.57], p < 0.0001), and the use of anti-migraine drugs (OR: 2.61, CI: [1.37–4.99], p = 0.004) compared to MS. Conclusion: Only about half of RIS patients had MS-selected healthcare resources, which allowed for data linkage. Those who did seek care before their RIS diagnosis were most commonly known for other neurological comorbidities. These findings do not support the idea of a systemic prodrome before RIS diagnosis.

13 May 2025 in Neurology
Verified
Journal Article
Closed access
OGOctave Guinebretiere
Octave Guinebretiere
CPChloe Pierret
Chloe Pierret
QCQuentin Calonge
Quentin Calonge
EJEdouard Januel
Edouard Januel
CLCeline Louapre
Celine Louapre
TNThomas Nedelec
Thomas Nedelec
Multiple sclerosis (MS) is a chronic neurologic disorder with significant implications for public health as being the first cause of nontraumatic neurologic disability in young adults. Although the global prevalence of MS has been increasing, recent temporal trends in incidence remain unclear. We aimed to evaluate current MS incidence trends in France over 11 years using the Système National des Données de Santé, a nationwide administrative database covering 99% of the French population. We used a published algorithm that incorporates multiple data sources, including benefits from long-term diseases, specific disease-modifying treatment prescriptions, and hospital discharge, to identify incident MS cases from January 1, 2011, to December 31, 2021. Sex-standardized and age-standardized incidence and prevalence were estimated using a "specific" and a "sensitive" definition providing bounds on the evolution of recent incidence. We used multivariable Poisson regression models to estimate temporal trends in incidence rates, calculating incidence rate ratios (IRRs) along with corresponding 95% CIs. In a sensitivity analysis, the time lag between past visits to neurologists and the database recording of MS was analyzed to ensure that the diagnosis extraction date was reliable. A total of 67,311 individuals with suspected MS were identified between 2011 and 2021, with 50,320 individuals classified as incident MS using the specific definition. The sensitive definition identified 56,918 individuals with incident cases. The median age at diagnosis was 40.6 years for the specific definition and 41.5 years for the sensitive definition. The study found stable incidence of MS over the 11-year period (adjusted IRR: 0.998 [95% CI 0.996-1.001] for the specific cohort). The female-to-male ratio of incident MS cases remained stable while sex-standardized and age-standardized prevalence of MS continued to rise. The median time lag between probable diagnosis and database recording was estimated to be less than 18 months, with variations depending on age and method of patient identification. This study provides a comprehensive analysis of MS epidemiology in France, demonstrating stable incidence and sex ratio. The increase in prevalence suggests improved management and survival and highlights the ongoing need for health care systems to support the growing population of individuals with MS.

5 April 2026 in Multiple Sclerosis Journal
Verified
Journal Article
Open access
CPChloe Pierret
Chloe Pierret
GAGeraldine Androdias
Geraldine Androdias
CLChristine Lebrun-Frenay
Christine Lebrun-Frenay
SVSandra Vukusic
Sandra Vukusic
MMMyriam Maumy
Myriam Maumy
ELEmmanuelle Leray
Emmanuelle Leray
Background: Neurological care and disease-modifying therapies (DMTs) are central to multiple sclerosis (MS) management, but how comorbidities like cancer affect them remains unclear. Objective: We assessed the impact of cancer on MS-related healthcare and DMT use. Methods: This cohort study accessed population-based data from France (2009–2021) and British Columbia, Canada (1991–2020). Cases were individuals with MS diagnosed with an incident cancer. The 4-year study period encompassed the 2 years before and after the cancer diagnosis. Each case was matched to two cancer-free individuals with MS (i.e. controls). Outcomes were neurologist visit rates, MS hospitalization rates, and percentage of DMT users. Mixed-effects models were used with a knot at cancer diagnosis. Incidence rate ratios (IRRs) were estimated pre- and post-cancer (cases vs. controls) and compared using a slope ratio (SR). Results: In total, 6902 cases were matched to 13,804 controls. There was a negative effect of cancer on DMT use (SR = 0.36 [0.19–0.70]), especially among those on chemotherapy (SR = 0.24 [0.14–0.40]). Neurologist visit IRRs did not differ pre- and post-cancer (SR = 0.96 [0.91–1.005]). Similarly, MS hospitalization IRRs did not differ (SR = 1.06 [0.84–1.33]). Conclusion: Following cancer, DMT use declined sharply. However, there was no evidence of a strong impact of cancer on neurologist visits and MS hospitalizations.

16 May 2025 in European Journal of Neurology
Verified
Journal Article
Open access
CPChloe Pierret
Chloe Pierret
LPLou Philippe
Lou Philippe
ELEmmanuelle Leray
Emmanuelle Leray
Background: There is little information on breast cancer screening (BCS) practices in women with multiple sclerosis (WwMS).Objective: To assess and compare BCS rates in WwMS and in the general population and identify barriers and facilitators.Methods: In a 2012–2020 cohort study, we identified 47,166 WwMS without a history of cancer and matched them (up to 1:4) to 184,124 controls from the French national medico‐administrative database. Mammography rates were compared according to age, city‐level socio‐economic status, period, and DMT use. We used logistic and negative binomial models to identify factors associated with BCS adherence in WwMS. We also carried out semistructured interviews with 20 WwMS and analyzed them using the empirically inductive method.Results: Compared with controls, fewer WwMS underwent BCS at least once (69.9% vs. 76.7%, p < 0.001) and had a lower biennial mammography rate (0.55 vs. 0.63; p < 0.001). Rate differences increased with age. Once stratified on DMT, age‐standardized rates only differed in the non‐treated group (0.51 vs. 0.64; p < 0.001). Factors associated with lower mammography rates in WwMS were city‐level socio‐economic status (mostdeprived vs. least deprived; IRR 0.88 95% CI [0.86–0.91]), long MS duration (16–25 years: 0.91 [0.89–0.94]; ref: ≤ 5) and hospitalization (MS‐related: 0.85 [0.82–0.88]; non‐MS‐related: 0.92 [0.89–0.94]). However, DMT use was associated with higher mammography rates (high efficacy: 1.17 [1.14–1.21]; moderate efficacy: 1.18 [1.16–1.20]). Barriers were physical disability and feeling of excessive medicalization. Facilitators were disability‐accessible care and perception of BCS as a routine procedure.Conclusion: BCS among WwMS is suboptimal, especially among those not treated by DMT, and needs to be improved.